Exclusive Licence Agreement

27/03/2015

Rexgenero Ltd enters into exclusive licence agreement with FundaciĆ³n Progreso y Salud (FPS) and the Servicio Andaluz de Salud (SAS) for the worldwide development and commercialisation of cellular therapies for the treatment of peripheral arterial disease.

innovative cell therapies
Contact us